-
Editorial Comment
Stroke prevention in non-valvular atrial fibrillation with rivaroxaban.
- Cardiovasc J Afr. 2014 Jul 1; 25 (4): 196.
AbstractThe new oral anticoagulants are the way of the future when it comes to stroke prevention in atrial fibrillation (AF). The ROCKET-AF trial showed that not only was rivaroxaban non-inferior to warfarin for preventing stroke and systemic embolism, but safer too.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:

- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.